Article Figures & Data
Figures
- FIGURE 1.
18F-DCFPyL PET maximum-intensity projections representative of tracer distribution. (A) Normal biodistribution (significant uptake by lacrimal glands, salivary glands, kidneys, liver, spleen, bowel, and bladder content). (B) Metastatic prostate cancer.
- FIGURE 2.
Proportion of positive scans based on PSA level. Error bars represent 95% confidence intervals.
Tables
All included BR after RP only* BR after RT only* Variable Data n Data n Data n Age (y) 69.1 ± 6.5 130 68.4 ± 6.3 92 70.8 ± 6.9 35 Body weight (kg) 87.4 ± 14.4 130 86.9 ± 14.4 92 87.7 ± 13.5 35 Height (cm) 177.3 ± 6.8 130 176.9 ± 6.8 92 177.5 ± 6.6 35 Injected activity (MBq) 369.2 ± 47.2 130 367.8 ± 47.1 92 371.1 ± 46.0 35 Uptake time (min) 120.4 ± 1.5 130 120.5 ± 1.7 92 120.2 ± 0.6 35 Inclusion criteria† Known PC after radical prostatectomy with BR 94 (72.3%) 130 92 (100%) 92 0 (0.0%) 35 Known PC after radiation therapy with BR 37 (28.5%) 130 0 (0.0%) 92 35 (100%) 35 PSA at baseline (ng/mL) 5.20 ± 6.50 130 3.03 ± 3.40 92 11.11 ± 8.94 35 PSA doubling time (mo) 12.2 ± 11.8 113 12.0 ± 12.3 78 12.9 ± 11.1 32 Treatment history† Surgery 94 (72.3%) 130 92 (100%) 92 0 (0.0%) 35 Radiotherapy† 45 (34.6%) 130 7 (7.6%) 92 35 (100%) 35 Brachytherapy 27 (60.0%) 45 0 (0.0%) 7 26 (74.3%) 35 External-beam therapy 20 (44.4%) 45 5 (71.4%) 7 13 (37.1%) 35 Intensity-modulated radiation therapy 4 (8.9%) 45 2 (28.6%) 7 2 (5.7%) 35 Proton therapy 1 (2.2%) 45 0 (0.0%) 7 1 (2.9%) 35 223RaCl2 0 (0.0%) 45 0 (0.0%) 7 0 (0.0%) 35 Androgen-deprivation therapy 62 (47.7%) 130 39 (42.4%) 92 22 (62.9%) 35 Chemotherapy 1 (0.8%) 130 1 (1.1%) 92 0 (0.0%) 35 All included BR after RP only* BR after RT only* Variable Data n Data n Data n Number of lesions 130 92 35 0 20 (15.4%) 19 (20.7%) 0 (0.0%) 1 53 (40.8%) 35 (38.0%) 18 (51.4%) 2 11 (8.5%) 6 (6.5%) 5 (14.3%) 3 6 (4.6%) 6 (6.5%) 0 (0.0%) 4 3 (2.3%) 3 (3.3%) 0 (0.0%) 5 7 (5.4%) 5 (5.4%) 2 (5.7%) 6–10 14 (10.8%) 10 (10.9%) 3 (8.6%) >10 16 (12.3%) 8 (8.7%) 7 (20.0%) Sites of relapse† 130 92 35 Local 35 (26.9%) 13 (14.1%) 22 (62.9%) Regional nodes 57 (43.8%) 41 (44.6%) 14 (40.0%) Distant nodes 32 (24.6%) 21 (22.8%) 10 (28.6%) Bone 26 (20.0%) 20 (21.7%) 6 (17.1%) Lung 3 (2.3%) 2 (2.2%) 1 (2.9%) Liver 0 (0.0%) 0 (0.0%) 0 (0.0%) Other 1 (0.8%) 1 (1.1%) 0 (0.0%) Diagnosis 130 92 35 Positive 110 (84.6%) 73 (79.3%) 35 (100%) Negative 20 (15.4%) 19 (20.7%) 0 (0.0%) Certainty of diagnosis 130 92 35 High 106 (81.5%) 73 (79.3%) 31 (88.6%) Moderate 17 (13.1%) 14 (15.2%) 3 (8.6%) Low 7 (5.4%) 5 (5.4%) 1 (2.9%) - TABLE 3
Changes in Treatment Intent, Disease Stage, Investigation, Decision Making, or Management Plan
All included BR after RP only* BR after RT only* Variable Data n Data n Data n Change in treatment intent 36 (65.5%) 55 21 (56.8%) 37 13 (86.7%) 15 To palliative 18 (50.0%) 36 10 (47.6%) 21 6 (46.2%) 13 To curative 18 (50.0%) 36 11 (52.4%) 21 7 (53.8%) 13 Change in disease stage 36 (65.5%) 55 24 (64.9%) 37 10 (66.7%) 15 Upstaged 34 (97.1%) 35 23 (100%) 23 9 (90.0%) 10 Downstaged 1 (2.9%) 35 0 (0.0%) 23 1 (10.0%) 10 Ordering of additional diagnostic studies† 13 (23.6%) 55 6 (16.2%) 37 7 (46.7%) 15 CT 4 (30.8%) 13 2 (33.3%) 6 2 (28.6%) 7 MRI 5 (38.5%) 13 3 (50.0%) 6 2 (28.6%) 7 Nuclear medicine 1 (7.7%) 13 1 (16.7%) 6 0 (0.0%) 7 Ultrasound 0 (0.0%) 13 0 (0.0%) 6 0 (0.0%) 7 Biopsy 4 (30.8%) 13 0 (0.0%) 6 4 (57.1%) 7 Other‡ 1 (7.7%) 13 0 (0.0%) 6 1 (14.3%) 7 Imaging results changed plans for surgery or biopsy 14 (25.5%); NA 13 (23.6%) 55 6 (16.2%); NA 10 (27.0%) 37 8 (53.3%); NA 1 (6.7%) 15 Surgery or biopsy added 9 (64.3%) 14 4 (66.7%) 6 5 (62.5%) 8 Surgery or biopsy cancelled 5 (35.7%) 14 2 (33.3%) 6 3 (37.5%) 8 Other 0 (0.0%) 14 0 (0.0%) 6 0 (0.0%) 8 Imaging results changed plans for systemic therapy 31 (56.4%); NA 3 (5.5%) 55 20 (54.1%); NA 2 (5.4%) 37 9 (60.0%); NA 1 (6.7%) 15 Systemic therapy started 23 (74.2%) 31 15 (75.0%) 20 6 (66.7%) 9 Systemic therapy not initiated/cancelled 8 (25.8%) 31 5 (25.0%) 20 3 (33.3%) 9 Systemic therapy changed 0 (0.0%) 31 0 (0.0%) 20 0 (0.0%) 9 Imaging results changed plans for radiotherapy 26 (47.3%); NA 9 (16.4%) 55 22 (59.5%); NA 6 (16.2%) 37 4 (26.7%); NA 1 (6.7%) 15 Radiotherapy added 13 (52.0%) 25 11 (52.4%) 21 2 (50.0%) 4 Radiotherapy cancelled 9 (36.0%) 25 8 (38.1%) 21 1 (25.0%) 4 Radiotherapy prescription changed 3 (12.0%) 25 2 (9.5%) 21 1 (25.0%) 4 Imaging results improved decision making 49 (89.1%) 55 33 (89.2%) 37 14 (93.3%) 15 Imaging results changed subject’s management plan 48 (87.3%) 55 32 (86.5%) 37 14 (93.3%) 15
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Changes in Management After 18F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes
- Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy
- 18F-DCFPyL PET Acquisition, Interpretation, and Reporting: Suggestions After Food and Drug Administration Approval
- Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance
- The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study
- 18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy
- Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management
- Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment